CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC PORCINE

All Clinical Trials for secretin synthetic porcine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	National Institute on Deafness and Other Communication Disorders (NIDCD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 ↗	Secretin for the Treatment of Autism	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1999-06-01	Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00620919 ↗	Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Multidetector Computed Tomography (MDCT) of the pancreas. 2. To demonstrate that RG1068-enhanced MDCT improves image quality of the pancreas in patients with chronic pancreatitis. 3. To evaluate if RG1068 enhanced MDCT results in improved delineation of structural abnormalities of the pancreatic duct as compared to non-enhanced MDCT.
NCT00621283 ↗	Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography. 2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic pancreatitis. 3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the pancreatic duct as compared to the non-enhanced MRCP. 4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the duodenum and the apparent diffusion coefficient of the pancreas.
NCT00621556 ↗	Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas	Terminated	Massachusetts General Hospital	Phase 1	2008-02-01	1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography 2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients with suspected IPMN 3. To correlate findings on MRCP with histologically confirmed malignancy

Clinical Trial Conditions for secretin synthetic porcine

Condition Name

Condition Name for secretin synthetic porcine
Intervention	Trials
Chronic Pancreatitis	2
Acute Recurrent Pancreatitis	1
Autism	1
Intraductal Papillary Mucinous Neoplasms	1

Condition MeSH

Condition MeSH for secretin synthetic porcine
Intervention	Trials
Pancreatitis, Chronic	2
Pancreatitis	2
Neoplasms	1
Autistic Disorder	1

Clinical Trial Locations for secretin synthetic porcine

Trials by Country

Trials by Country for secretin synthetic porcine
Location	Trials
United States	5

Trials by US State

Trials by US State for secretin synthetic porcine
Location	Trials
Massachusetts	3
Washington	1
Colorado	1

Clinical Trial Progress for secretin synthetic porcine

Clinical Trial Phase

Clinical Trial Phase for secretin synthetic porcine
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	3

Clinical Trial Status

Clinical Trial Status for secretin synthetic porcine
Clinical Trial Phase	Trials
Terminated	3
Completed	1

Clinical Trial Sponsors for secretin synthetic porcine

Sponsor Name

Sponsor Name for secretin synthetic porcine
Sponsor	Trials
Massachusetts General Hospital	3
National Institute on Deafness and Other Communication Disorders (NIDCD)	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1

Sponsor Type

Sponsor Type for secretin synthetic porcine
Sponsor	Trials
Other	3
NIH	2

Last updated: June 1, 2026

Secretin (Synthetic Porcine) Clinical Trials Update, Market Analysis, and 2026-2036 Projection

What is synthetic porcine secretin and what is it used for?

Synthetic porcine secretin is a peptide drug used in gastrointestinal diagnostics, most notably to evaluate pancreatic exocrine function via secretin stimulation testing. Commercially, the product category is typically small-volume, specialty-distribution, and tied to GI functional testing workflows rather than broad therapeutic use.

What is the current regulatory status of synthetic porcine secretin in the US?

No complete, current dataset (FDA approval labels, Orange Book exclusivity, NDA/BLA identifiers, or pending supplements) is provided in the input, and generating an accurate trial and market projection without anchoring to the actual marketed product’s FDA history would be incomplete.

What clinical trials are ongoing or recently completed for secretin (synthetic porcine)?

No trial registry identifiers (NCT numbers), therapeutic/indication scope, or recent results are provided. A reliable “clinical trials update” requires at minimum trial IDs and key endpoints to avoid misstatement.

How big is the market for synthetic porcine secretin and what drives demand?

No market size, pricing, US vs EU share, utilization by hospital type, payer coverage details, or sales base-year figures are provided. Demand modeling without baseline commercial metrics would be speculative.

When does synthetic porcine secretin face competitive pressure from generics or alternatives?

No FDA exclusivity or patent/Orange Book status is provided. Without the product’s reference listing, exclusivity timers, and identified competitors, an exclusivity-to-generic timeline would be inaccurate.

What is the revenue projection for secretin (synthetic porcine) through 2036?

No historical sales data, reimbursement benchmarks, or geographies are supplied. A quantified forecast cannot be produced without an underlying reference point.

What is the likely impact of manufacturing, supply constraints, and drug availability on market outcomes?

No manufacturer information, supply history, FDA inspection outcomes, or known stock/shortage events are provided. These materially alter projections for specialty diagnostic peptides, so a factual forecast cannot be built from absent inputs.

What alternative products could substitute for secretin stimulation tests and how does that affect the outlook?

No comparative landscape (other secretin products, recombinant secretin approaches, imaging protocol substitutions, or functional testing alternatives) is supplied. Substitution risk changes the demand curve.

Key takeaways

• A defensible clinical-trials update and quantified 2026-2036 market projection for synthetic porcine secretin requires product-specific regulatory anchors (FDA listing, label/approval history, Orange Book status) and trial-level identifiers (NCT or equivalent), neither of which are provided in the input.
• Generating numbers or timelines without those anchors would create a high risk of factual error.

FAQs

1. What endpoints are typically used in secretin stimulation diagnostic trials?
2. How do reimbursement policies influence use of secretin stimulation testing?
3. What regulatory pathway applies to additional secretin formulations or manufacturing changes?
4. How do shortages of specialty diagnostic peptides affect hospital ordering patterns?
5. What competitive alternatives reduce utilization of secretin-based testing?

References

No sources were provided in the input.